Cargando…
Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
BACKGROUND: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646558/ https://www.ncbi.nlm.nih.gov/pubmed/38027106 http://dx.doi.org/10.3389/fendo.2023.1293093 |
_version_ | 1785134921110519808 |
---|---|
author | Stenlid, Rasmus Cerenius, Sara Y. Wen, Quan Aydin, Banu Küçükemre Manell, Hannes Chowdhury, Azazul Kristinsson, Hjalti Ciba, Iris Gjessing, Erik S. Mörwald, Katharina Gomahr, Julian Heu, Verena Weghuber, Daniel Forslund, Anders Bergsten, Peter |
author_facet | Stenlid, Rasmus Cerenius, Sara Y. Wen, Quan Aydin, Banu Küçükemre Manell, Hannes Chowdhury, Azazul Kristinsson, Hjalti Ciba, Iris Gjessing, Erik S. Mörwald, Katharina Gomahr, Julian Heu, Verena Weghuber, Daniel Forslund, Anders Bergsten, Peter |
author_sort | Stenlid, Rasmus |
collection | PubMed |
description | BACKGROUND: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT. SUBJECTS AND MEASUREMENTS: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses. RESULTS: Exenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT. CONCLUSION: Weekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, identifier NCT02794402 |
format | Online Article Text |
id | pubmed-10646558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106465582023-01-01 Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control Stenlid, Rasmus Cerenius, Sara Y. Wen, Quan Aydin, Banu Küçükemre Manell, Hannes Chowdhury, Azazul Kristinsson, Hjalti Ciba, Iris Gjessing, Erik S. Mörwald, Katharina Gomahr, Julian Heu, Verena Weghuber, Daniel Forslund, Anders Bergsten, Peter Front Endocrinol (Lausanne) Endocrinology BACKGROUND: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT. SUBJECTS AND MEASUREMENTS: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses. RESULTS: Exenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT. CONCLUSION: Weekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, identifier NCT02794402 Frontiers Media S.A. 2023-11-01 /pmc/articles/PMC10646558/ /pubmed/38027106 http://dx.doi.org/10.3389/fendo.2023.1293093 Text en Copyright © 2023 Stenlid, Cerenius, Wen, Aydin, Manell, Chowdhury, Kristinsson, Ciba, Gjessing, Mörwald, Gomahr, Heu, Weghuber, Forslund and Bergsten https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Stenlid, Rasmus Cerenius, Sara Y. Wen, Quan Aydin, Banu Küçükemre Manell, Hannes Chowdhury, Azazul Kristinsson, Hjalti Ciba, Iris Gjessing, Erik S. Mörwald, Katharina Gomahr, Julian Heu, Verena Weghuber, Daniel Forslund, Anders Bergsten, Peter Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title_full | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title_fullStr | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title_full_unstemmed | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title_short | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
title_sort | adolescents with obesity treated with exenatide maintain endogenous glp-1, reduce dpp-4, and improve glycemic control |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646558/ https://www.ncbi.nlm.nih.gov/pubmed/38027106 http://dx.doi.org/10.3389/fendo.2023.1293093 |
work_keys_str_mv | AT stenlidrasmus adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT cereniussaray adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT wenquan adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT aydinbanukucukemre adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT manellhannes adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT chowdhuryazazul adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT kristinssonhjalti adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT cibairis adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT gjessingeriks adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT morwaldkatharina adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT gomahrjulian adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT heuverena adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT weghuberdaniel adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT forslundanders adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT bergstenpeter adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol |